Literature DB >> 2201343

Current status of cancer drug development: failure or limited success?

G B Grindey1.   

Abstract

Murine leukemia models have been a major part of cancer drug screening strategies over the past 30 years. While these models have reliably identified agents active against human leukemias and lymphomas, they have been considerably less effective in identifying new agents for the treatment of common human solid tumors. This review considers the shortcomings of past approaches to cancer drug development, and describes new screening strategies designed to identify carcinoma-selective drugs.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2201343

Source DB:  PubMed          Journal:  Cancer Cells        ISSN： 1042-2196


  9 in total

1.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors:  L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.

Authors:  R Brand; M Capadano; M Tempero
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 3.  Effects of sulfonylureas on tumor growth: a review of the literature.

Authors:  Giulia Pasello; Loredana Urso; Pierfranco Conte; Adolfo Favaretto
Journal:  Oncologist       Date:  2013-09-16

4.  Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screening.

Authors:  M J Murphy; F Fushimi; R E Parchment; E Barberá-Guillem
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Synthesis, characterization, antioxidant activity and DNA-binding studies of three rare earth (III) complexes with 1-(4-aminoantipyrine)-3-tosylurea ligand.

Authors:  Pin-xian Xi; Zhi-hong Xu; Xiao-hui Liu; Feng-juan Chen; Zheng-zhi Zeng; Xiao-wen Zhang; Ying Liu
Journal:  J Fluoresc       Date:  2008-06-04       Impact factor: 2.217

6.  Effect of cisplatin on primary tumour growth and liver metastases in the M 5076 reticulum sarcoma: implication for new screening modalities.

Authors:  M Schirner; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Chemotherapy of mammary carcinomas arising in ras transgenic mice.

Authors:  D L Dexter; M Diamond; J Creveling; S F Chen
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

8.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Authors:  S Dhar; P Nygren; K Csoka; J Botling; K Nilsson; R Larsson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

9.  Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.

Authors:  G Pezzoni; M Grandi; G Biasoli; L Capolongo; D Ballinari; F C Giuliani; B Barbieri; A Pastori; E Pesenti; N Mongelli
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.